Scalper1 News
At a time when most leading biotechs are still trying to recover from the Aug. 24 market sell-off, Sucampo Pharmaceuticals (SCMP) is running far ahead of the pack. Shares of the specialty drugmaker are well extended past a 22.10 buy point and subsequent rebound off the 10-week moving average. They’re up more than 80% this year vs. the Nasdaq’s 3% gain. The Bethesda, Md.-based company develops drugs based on prostones, compounds derived from fatty Scalper1 News
Scalper1 News